Spanish biotech Oryzon slumps as Roche ditches cancer drug

(Reuters) - Shares in Spanish biotech company Oryzon Genomics plunged 30 percent on Thursday after Swiss drugmaker Roche pulled out of a deal to develop its leading experimental drug for leukemia and lung cancer.